In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the ...

Eli Lilly has now submitted a new drug application (NDA) for GLP-1RA orforglipron to the FDA for use in adults with obesity.

Propelled by a flurry of dealmaking late in the year, 2025 M&A ended on a strong note, with high activity expected to ...

Zasocitinib is also being evaluated in a head-to-head study against Bristol Myers Squibb’s Sotyktu (deucravacitinib) in ...

Shares in Tokyo-listed Nxera Pharma slid 5% at market open after Boehringer walked away from the neurological assets.

Large deals in H2 2025 included Novartis’ $12 billion acquisition of Avidity Biosciences and Genmab’s buyout of Merus, ...

Alnylam Pharmaceuticals is to invest $250m to expand its facility in Massachusetts, US, to meet the growing demand for RNAi ...

Depo Provera’s label change comes amidst a flurry of over 2,000 lawsuits from women alleging that the contraceptive caused ...

INCOG BioPharma Services has announced an injectable drug manufacturing expansion at its Fishers facility in Indiana, US.

Sobi has signed an agreement for the acquisition of US-based biotechnology company Arthrosi Therapeutics for $950m.

Targeted patient recruitment can increase the likelihood of trial success and help cultivate use of precision medicine.

Harbour BioMed and Bristol Myers Squibb (BMS) have signed a multi-year, worldwide strategic partnership and licence agreement ...